Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NZV930 |
Synonyms | |
Therapy Description |
NZV930 is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 31461341). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NZV930 | SRF373|SRF-373|SRF 373|NZV 930|NZV-930 | Adenosine Targeting 24 CD73 Antibody 13 | NZV930 is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 31461341). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03549000 | Phase I | NZV930 + Spartalizumab + Taminadenant NZV930 + Spartalizumab NZV930 + Taminadenant NZV930 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | Terminated | USA | GBR | ESP | CAN | AUS | 2 |